Groundbreaking New Product And Strong Revenue Growth News Could Fuel Nasdaq Past Champ (BTCY) To A Vertical Surge

The opening bell is here so let's get to it quickly... Groundbreaking New Product And Strong Revenue Growth News Could Fuel Nasdaq Past Champ (BTCY) To A Vertical Surge My Last Profile Surged Approximately 8,515% Intraday... December 27th Dear Reader, The opening bell is here so let's get to it quickly... This past Wednesday, I brought you an idea that set the markets on fire. From an open of $.0095, BWTX ran wild to a high of $.8099 on the day. That approximate move of 8,515% intraday made BWTX one of our biggest alerts to date. But I'm not looking to rest and just cruise on into 2022. Instead, I've been keeping tabs on another former champ that ran approximately $2.00+ in under a month when I brought it to your attention. Brought to your attention for the morning of October 7th, 2021, this Nasdaq idea opened at $2.95 and hit a $4.99 high on November 4th. Making an approximate 69% short term run, this profile became one of our normal breakout champs of the year. Now, due to several potential catalysts, it could be fueled up for round 2. For the morning of December 27th, there is only one profile to have on your radar: *Biotricity, Inc. (BTCY)* Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic products for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. Its Foundational Product, Bioflux, is Targeting a Growing and Underserved Market The company’s first and primary solution, Bioflux, addresses the growing and underserved Mobile Cardiac Telemetry (MCT) market. Bioflux is a high-precision, single-unit MCT device providing real-time monitoring and transmission of ECG information from ambulatory patients. This entire system is a complete solution for remote cardiac monitoring that merges seamlessly with physicians’ existing platforms and workflows to better detect, diagnose, and monitor. For medical practitioners, this solution looks to be technologically superior and more financially attractive too. Clinicians designed the Bioflux online portal for clinicians. After all, the prime features of the product were built after speaking with numerous healthcare professionals and seeing what their most requested features were. And right now, BTCY has 5 potential catalysts that could spark a possible breakout. Here's what you need to know... No. 1 Potential BTCY Breakout Catalyst - Bioheart Heart Monitor Product Now Available Biotricity Delivers Bioheart, A Groundbreaking Consumer Heart Monitor Continuous monitoring device with advanced features and analytics to deliver personalized insights directly to the smartphone REDWOOD CITY, Calif., November 10, 2021--(BUSINESS WIRE)--Biotricity, Inc. (NASDAQ:BTCY), a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions, today announced the availability of Bioheart, a direct-to-consumer heart monitor that offers the same continuous heart monitoring technology used by physicians. Showcased in prototype form at CES 2020, Bioheart has shipped to preorder customers and is now available for purchase at www(dot)bioheart(dot)com. The launch of Bioheart opens a new market and revenue stream for Biotricity while expanding the company’s total addressable market by $1.24B, the global heart rate monitoring market. "Launching Bioheart and expanding into this new market is an important step for Biotricity and our ultimate goal of building a complete cardiac ecosystem to service individuals throughout their heart health journey," said Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. [...] [Read the full article here.]( ----- No. 2 Potential BTCY Breakout Catalyst - Strong Balance Sheet And Revenue Growth Announcement Biotricity Releases Fiscal 2022 Second Quarter Fin-an-cial Results - Company reports tenth consecutive quarter of triple-digit year-over-year revenue growth - Strongest balance sheet since inception REDWOOD CITY, CA / ACCESSWIRE / November 4, 2021 /Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced fin-an-cial results for its 2022 fiscal year's second quarter ended September 30, 2021. [...] "This was a historic quarter with our recent listing on the Nasdaq, in which we strengthened our balance sheet, and introduced our plans for Biokit and its commercial launch in the first quarter of calendar 2022," stated Dr. Waqaas Al-Siddiq, CEO and founder of Biotricity. "We have disclosed several other state-of-the-art remote cardiac monitoring devices and software apps in our development pipeline - all of which are planned for commercialization in 2022, pending FDA clearance where required." [...] [Read the full article here.]( ----- No. 3 Potential BTCY Breakout Catalyst - Bullish Technical Indicators Cover Short, Medium, And Long Term At close this past Thursday, [Barchart]( was reporting BTCY to have a ton of bullish technical indicators. Here's a list of the triggered ones to pay close attention to: Short Term Indicators - 20 - 50 Day MACD Oscillator - 20 - 100 Day MACD Oscillator - 20 - 200 Day MACD Oscillator Medium Term Indicators - 50 - 100 Day MACD Oscillator - 50 - 150 Day MACD Oscillator - 50 - 200 Day MACD Oscillator Long Term Indicators - 100 Day Moving Average - 150 Day Moving Average - 200 Day Moving Average - 100 - 200 Day MACD Oscillator On top of that, Barchart is reporting BTCY to be a "100% BUY" based on its long term technical indicators. ----- No. 4 Potential BTCY Breakout Catalyst - Major Price Targets From 4 Different Analysts/Firms Since July 1st, four different analysts have provided price targets of either $6.00 or $7.00 according to [MarketBeat's website](. Check them out: [H.C. Wainwright]( analyst, Kevin Dede, commented: "We are initiating coverage of Biotricity with a Buy rating and setting a potentially conservative $6 price target not only on account of the horizontal expansion marketing its solution in cardiac care to 25,000 U.S. physicians, but also on the profound trajectory toward the full ecosystem of care monitoring solutions for cardiac-related and/or influenced chronic conditions such as diabetes, hypertension, kidney disease, among others. And while Biotricity has growth avenues to incorporate artificial intelligence-driven automation into its remote monitoring of many facets of holistic cardiac care—the vertical expansion alluded to—we see Biotricity, on its cardiac solution, Bioflux, alone presenting an enticing in-vest-ment as Bioflux supports better outcomes while providing doctors avenues to offer greater services. With the support of a fully FDA approved device and multiple insurance codes, Bioflux produces electrocardiogram (ECG or EKG) results while patients are living their normal lives. The readings, stored in the cloud, present physiological insight for physicians in determining the next course of action in long-term care, and in the meantime, doctors may choose an alternative course and demand another office visit, an additional income event beyond the only-a-phone-visit 'telehealth' financial paradigm. For this reason, in concert with broad insurance coverage—sensible, we think, in light of physically fragile patients needing full-time monitoring in recognizing a negative trigger event—we expect doctors to continue to buy and use Biotricity's Bioflux. For perspective on scale, at $500 each, and roughly 2,000 patients per each of the 25,000 base U.S. cardiac physicians, that when added to additional devices and services required to address associated cardiac-related afflictions, points to a $50B addressable market, and greater detail on this assessment is provided later in this report. From our perspective, longer-term targets tied to kidney disease and other associated cardiac issues, fail our need for tangible solutions from which to base projections and are not powering our current forecasts; however and more importantly, the development of the monitoring ecosystem clearly supports the large addressable opportunity point. Nearer-term growth comes on the addition of new sales professionals, filling out an effort Biotricity has not grandly supported to date, and where we expect their addition to drive the steep immediate sales ramp forecast here." ----- No. 5 Potential BTCY Breakout Catalyst - Shareholder Update Claims Company "Well-Positioned For 2022" Biotricity, a Leader in Remote Cardiac Health Monitoring Solutions, Issues Company Roadmap in 2021 Shareholder Letter The Company believes that it is "well-positioned for 2022." Letter highlights milestones, products roadmap, growth strategy and 2022 goals REDWOOD CITY, CA / ACCESSWIRE / December 7, 2021 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, has released its December 2021 CEO Shareholder Letter, which discusses recent Company milestones achieved including its financial performance, commercialization of its new Biokit, and other state-of-the-art remote cardiac monitoring devices and software apps in development. Highlights from the shareholder letter include: - Recent uplisting to Nasdaq that the Company believes will help further attract a larger pool of sophisticated institutional in-vest-ors, and a potential increase in liquidity and visibility - Commercialization of the personal medical 3-devices kit, Biokit, for integration into the Biotricity ecosystem - Record quarterly revenue of $1.81Mn for its 2022 fiscal year's second quarter ended September 30, 2021, up 143% year-over-year - its tenth consecutive quarter of triple-digit year-over-year growth - The product roadmap for Bioflux®, Biotres, Biocare® Telemed, Biokit, and Bioheart - The Company's 2022 goals include launching new state-of-the-art cardiac monitoring solutions and software services. Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity commented, "We had a historic second quarter that saw revenue increase 143% YoY, the strengthening of our balance sheet, and uplisting to Nasdaq which has boosted our exposure to in-vest-ors worldwide. We've made great strides in each vertical we targeted over the year and are well-positioned to continue the execution of our overall growth plan for 2022. We seek to take telemedicine to a new, next-generation level of cost-effectiveness as well as disrupt the cardiac care landscape by reducing patient care costs with improved patient outcomes." [Read the full article here.]( ----- BTCY Recap: 5 Potential Breakout Catalysts For This Nasdaq MedTech Profile No. 1 - Bioheart Heart Monitor Product Now Available No. 2 - Strong Balance Sheet And Revenue Growth Announcement No. 3 - Bullish Technical Indicators Cover Short, Medium, And Long Term No. 4 - Major Price Targets From 4 Different Analysts/Firms No. 5 - Shareholder Update Claims Company "Well-Positioned For 2022" Coverage is officially reinitiated on BTCY. When you have time later, do this: Get BTCY on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer  I am not a lic-ensed fina-ncial adviser. All potential percentage gains are based on from the low to the high of day. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> StockWireNews (stockwirenews . com) is owned by StockNewsWire LLC, a limited liability company. An owner of StockNewsWire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a period beginning on 9/15/21 and ending on 9/16/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. We were paid fifteen thousand USD via ACH. We own zero shares of (BTCY). An owner of StockNewsWire LLC owns an interest in FierceInvestor. Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 9/15/21 and ending on 9/16/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid sixty-seven thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a period beginning on 10/7/21 and ending on 10/8/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. We were paid two thousand five hundred USD via ACH. We own zero shares of (BTCY). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 10/7/21 and ending on 10/8/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid fifteen thousand USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a one day period beginning on 10/29/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. We were paid two thousand five hundred USD via ACH. We own zero shares of (BTCY). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a one day period beginning on 10/29/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid ten thousand USD via bank wire transfer. StockWireNews owns zero shares of (BTCY).  Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a period beginning on 12/27/21 and ending on 12/28/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. We were paid five thousand USD via ACH. We own zero shares of (BTCY). To date we have been compensated a total of twenty-five thousand USD via ACH to disseminate information about (BTCY). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 12/27/21 and ending on 12/28/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid twenty-five thousand USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). To date we have been compensated a total of one hundred and seventeen thousand five hundred USD via bank wire transfer to disseminate information about (BTCY). We were not compensated for our profile on (BWTX). We own zero shares of (BWTX). Fierce | 539 W Commerce St, Dallas, TX 75208 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net